Introduction Lenvatinib (MK-7902) is a potent, oral, multi-targeted receptor tyrosine kinase inhibitor. It exerts its therapeutic effects by inhibiting key kinases involved in angiogenesis, tumor growth, and cancer progression, including VEGFR1-3, FGFR1-4, PDGFRA, KIT, and RET (1). Given its broad-spectrum activity, Lenvatinib has been investigated
241 Reached
Pregnant Woman with HIV-1 Infection
747 Reached1 Likes
Use of Clindamycin for Managing Bacterial Vaginosis
11195 Reached29 Comments8 Likes
Black Lesion in Old Female
1972 Reached5 Comments11 Likes
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1007 Reached2 Comments
Treatment of Recurrent Adult Medulloblastoma
2602 Reached1 Comments4 Likes